Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorder. It is hypothesized that these patients have dysregulated immune surveillance of EBV. We reviewed the biopsies of 55 patients with LYG who were referred for a prospective trial at the National Cancer Institute (1995 to 2010) and evaluated the histologic, immunohistochemical, in situ hybridization, and molecular findings of these biopsies in conjunction with clinical information. Grading of the lesions was based on morphologic features and the number of EBV-positive B cells. The median age was 46 years (M:F 2.2:1). Clinically, all patients had lung involvement (100%), with the next most common site being the central nervous system (38%). No patient had nodal or bone marrow disease. All patients had past EBV exposure by serology but with a low median EBV viral load. We reviewed 122 biopsies; the most common site was lung (73%), followed by skin/subcutaneous tissue (17%); other sites included kidney, nasal cavity, gastrointestinal tract, conjunctiva, liver, and adrenal gland. Histologically, the lesions showed angiocentricity, were rich in T cells, had large atypical B cells, and were positive for EBV. Grading was performed predominantly on the lung biopsy at diagnosis; they were distributed as follows: LYG grade 1 (30%), grade 2 (22%), and grade 3 (48%). Necrosis was seen in all grades, with a greater degree in high-grade lesions. Immunoglobulin gene rearrangement studies were performed, and a higher percentage of clonal rearrangements were seen in LYG grade 2 (50%) and grade 3 (69%) as compared with grade 1 (8%). LYG is a distinct entity that can usually be differentiated from other EBV-associated B-cell lymphoproliferative disorders on the basis of the combination of clinical presentation, histology, and EBV studies. Grading of these lesions is important because it dictates the treatment choice.
L ymphomatoid granulomatosis (LYG) is a rare angiocentric and angioinvasive Epstein-Barr virus (EBV)associated B-cell lymphoproliferative disorder (LPD) primarily involving the lungs that was first described by Liebow et al 1 in 1972. LYG initially was believed to be a T-cell LPD 2,3 on the basis of the predominance of T cells. Katzenstein et al 4 later reported that these lesions were EBV associated. In 1994, Guinee et al 5 demonstrated that EBV was present in the atypical B cells, which were clonal at least in some cases, by immunoglobulin rearrangement. LYG was included as a distinct disease entity in the 2001 World Health Organization (WHO) classification 6 and considered an LPD of indeterminate malignant potential. The initial grading of LYG was based on cellular composition, cytologic atypia, and necrosis 7 and later based on the density and number of EBV-positive large atypical B cells (LACs). However, in practice, the grading can be inconsistent and poorly reproducible among observers. The greatest difficulty for the diagnosis of LYG has been with grade 1 lesions because of the possible absence or paucity of EBV-positive atypical B cells.
Currently, it is still uncertain whether LYG represents a unique and rare disease or is part of the spectrum of EBV-associated B-cell LPDs. Earlier studies were likely confounded by the inclusion of T-cell and NK-cell lymphomas (formerly included in the diagnosis of angiocentric immunoproliferative lesion) with cases of LYG. 3, [8] [9] [10] More recently, it has been hypothesized that patients with LYG have defective immune surveillance of EBV-infected B cells particularly by the CD8-positive T cells. 7, 11 In the current study, we have examined the distribution of regulatory T cells (Tregs), as these cells have been implicated in suppressing normal T-cell immunity and the immune response to viral infections. 12 With regard to treatment, historical outcomes of patients treated with steroids and/ or chemotherapy have been poor (median survivals of 14 mo). 4 At the National Cancer Institute (NCI) in a prospective clinical trial, patients with LYG grades 1 and 2 have been treated with interferon a and grade 3 with immunochemotherapy (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab, DA-EPOCH-R). This therapy stratification has improved progression-free survival to 56% (median follow-up 5.1 y) in patients with LYG grade 1-2 and progression-free survival to 44% (median follow-up 32 mo) in patients with LYG grade 3. 13 As therapy for LYG is guided by grading, it is imperative to have a consistent, accurate, and adequate evaluation of these lesions. We report our institution's unique experience and the histologic, molecular, and immunophenotypic findings with this rare disease.
MATERIALS AND METHODS

Tissue Specimens and Immunohistochemical Studies
Biopsies from patients referred to the NCI over a 15-year period (1995 to 2010) with a potential diagnosis of LYG were retrieved from the archives of the Hematopathology Section of the Laboratory of Pathology. We reviewed biopsy material from 69 patients; 3 patients were previously reported in an earlier study, 14 which focused on the cutaneous manifestations. All formalin-fixed paraffin-embedded (FFPE) tissue biopsies were reviewed by the authors (E.S.J, S.P., and J.Y.S.), utilizing the criteria of the 2008 WHO classification. 15 Fourteen of 69 patients who were initially referred as possible LYG were excluded. The diagnoses on review were: NK/T cell lymphoma, nasal type (1), peripheral T-cell lymphoma, not otherwise specified (1), classical Hodgkin's lymphoma (4), and EBV positive polymorphic or monomorphic B-cell lymphoma, lacking features of LYG (8) .
Of the 55 patients who were included in the study, 34 (62%) had prior therapy before enrolling in the LYG clinical trial, whereas 19 patients (35%) did not, and for 2 patients it was unknown whether there was prior treatment (4%). For the patients who had prior treatment, both the pretherapy and posttherapy biopsies were reviewed.
Immunohistochemical studies were performed on FFPE tissue sections using the following panel of antibodies (CD20, CD3, CD30, CD15, CD4, CD8, CD56, LMP1, FOXP3, and CD25) on cases with available material according to previously published techniques. [16] [17] [18] [19] Selected cases were studied to assess the latency phenotype of EBV with additional stains for EBNA2 (clone PE2, mouse monoclonal, 1:500 dilution; Abcam, Cambridge, MA) and ZEBRA (clone BZ1, mouse monoclonal, 1:1600 dilution; Santa Cruz Biotechnology, Dallas, TX). Detection was performed with Ultraview-DAB from Ventana (Tucson, AZ). CD4, FOXP3, and CD25 were used to assess the frequency of Tregs in tissue sections and were enumerated as the number of positive cells/10 hpf. The same panel was applied to 3 cases of interstitial pneumonitis as controls. The study was approved by the NCI Institutional Review Board (protocol number NCI-94-C-0074, clinical trial number NCT00001379).
In Situ Hybridization for EBV-Encoded RNA
In situ hybridization for EBV-encoded RNA (EBER) was performed on FFPE tissue sections using an FITC-labeled oligonucleotide probe supplied by Ventana on an automated stainer (Ventana-Benchmark, Tucson, AZ). Visualization was achieved using the ISH iView system with alkaline-phosphatase and nitro-blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate substrate, with nuclear fast red as contrast. A positive control was run with all cases and stained appropriately.
Molecular Studies Immunoglobulin Polymerase Chain Reaction
DNA extraction was performed on FFPE with the QiaCUBE extraction platform using their proprietary buffer and proteinase K digestion. Polymerase chain reaction (PCR) was performed using consensus primers directed to V H framework (FR) III and joining region (J H ) of the immunoglobulin heavy chain gene (FRIII-IGH PCR) and to V H FR region II and the joining region (FRII-IGH PCR), according to the method of Ramasamy et al. 20 Testing for the IGk locus was additionally performed using the Biomed II primer set described by van Dongen et al 21 and supplied by InVivoScribe Technologies (IGK@ Gene Clonality Assay-ABI Fluorescence Detection, Cat#: 1-102-0031). These reactions interrogate rearrangements involving the Vk loci and Jk (tube A), the Vk locus and the kDE locus (tube B), and the k-intron RSS locus and the kDE locus (tube B). The products from all reactions were separated by capillary electrophoresis on an ABI 3130xl Genetic Analyzer and the electropherograms analyzed using GeneMapper software version 3.7 (ABI). For cases before 2008, PCR amplification for detecting monoclonal immunoglobulin heavy chain gene rearrangements was performed as previously described. 22 
T-cell Receptor Gene Rearrangement
DNA was extracted using the QIAamp DNA FFPE Tissue Kit according to the manufacturer's instructions with minor modifications. PCR for detection of T-cell receptor gene rearrangements (TRG) was performed as described by Lawnicki et al 23 using primers that interrogate all of the known Vg family members, and the Jg1/2, JP1/2, and JP joining segments. To allow for fluorescence detection, each joining region primer was covalently linked to a unique fluorescent dye. The products were analyzed by capillary electrophoresis on an ABI 3130xl Genetic Analyzer, and electropherograms were analyzed using GeneMapper software version 3.7 (ABI). For cases before 2008, PCR amplification for detecting monoclonal TRG was performed as previously described. 24 
EBV Virus Nuclear Antigen (EBNA2) PCR
PCR for detection of EBV was performed on an ABI 7900 using TaqMan technology and primers targeting the EBNA2 gene. Before 2007, the PCR detection of EBV was performed using the quantitative real-time PCR on 7900TH Sequence Detection System (Applied Biosystems). The products were analyzed using a fluorogenic internal probe specifically targeted to the EBNA2 gene.
RESULTS
Clinical Features
The median age of 55 patients included in this analysis was 46 years (range, 21 to 74 y) comprising 38 men and 17 women (M:F 2.2:1). Clinically, at presentation, all patients had lung involvement (100%), with the next most common site being the central nervous system (CNS) (38%), followed by liver (19%), skin (17%), and kidney (15%) ( Table 1 ). CNS and liver involvement by LYG were determined by radiography, whereas skin involvement was determined by physical examination and biopsies. Serum samples were assayed on admission for antibodies to EBV in 34/51 patients, and 32/34 patients (94%) had evidence of prior infection confirmed by viral capsid antigens for IgG (VCA-IgG). The median EBV viral load was 18 copies per 10 6 genome equivalent (range, 0 to 22,727). In addition, 51 patients also had evaluation of their cerebrospinal fluid (CSF) by EBNA2 PCR as part of their initial workup, as the CNS is a common site of involvement by LYG. There were 8 positive CSFs by EBNA2 PCR (1 LYG grade 1, 1 LYG grade 2, 5 LYG grade 3, 1 consistent with LYG), whereas the remaining 43 samples were negative.
We reviewed a total of 122 biopsies with features of LYG. The most common biopsy site was the lung (89/ 122, 73%), followed by the skin/subcutaneous tissue (21/ 122, 17%). Other sites included kidney (3), nasal cavity (4), gastrointestinal (GI) tract (2), conjunctiva (1), liver (1), and adrenal gland (1) ( Table 2 ). Staging bone marrow biopsies were performed in 35 patients, all of which were negative for involvement.
The distribution of the lung biopsies was as follow: 6/60 right middle lobe (10%), 16/60 right lower lobe (27%), 5/60 right upper lobe (8%), 21/60 left lower lobe (35%), and 12/60 left upper lobe (20%). The majority of biopsies were performed in the lower lobes (37/60, 62%). There were 29 lung biopsies that did not further specify the site. Pretherapy and posttherapy (eg, steroids, chemotherapy) biopsies received from referring hospitals to a large degree showed similar morphologic findings.
Categorizing cases on the basis of the highest grade, 16/54 patients (30%) were classified as LYG grade 1, 12/ 54 patients (22%) as LYG grade 2, and 26/54 patients (48%) as LYG grade 3, with 1 case not graded because of insufficient material. Grading was determined predominantly on the lung biopsies (50/54, 93%), whereas ex-trapulmonary sites (eg, nasal cavity, GI tract) made up the minority. Altogether, 90 biopsies were graded and were distributed as: 31/90 (35%) LYG grade 1, 17/90 (19%) LYG grade 2, and 40/90 (45%) LYG grade 3. Skin lesions were not graded and are separately described below.
Morphologic, In Situ Hybridization, and Immunophenotypic Findings of LYG
All lesions were angiocentric and had various degrees of angioinvasion and angiodestruction that involved a range of small to large caliber vessels ( Fig. 1 ). The infiltrate was polymorphous with an admixture of small lymphocytes and histiocytes; occasionally plasma cells were seen, but were not prominent. Neutrophils, eosinophils, multinucleated giant cells, and well-formed granulomas were not seen. The infiltrates tended to have a patchy distribution, often well circumscribed, and the surrounding lung parenchyma was largely unremarkable. A certain degree of coagulative necrosis was seen in all grades and usually lacked neutrophils and apoptotic bodies. It is noteworthy that focal necrosis was seen in 9/ 31 (29%) cases of LYG grade 1 (Fig. 2 ). However, more extensive necrosis (sometimes >50% of the area) was seen in LYG grades 2 and 3. "Ghost cells" were highlighted with CD20 immunostaining within the necrosis in grade 2 and 3 lesions. Secondary changes such as fibroblastic foci at the periphery of the lesion and intra-alveolar macrophages, as well as edema, could be seen, but frank organizing pneumonia was not a typical finding. Atypical medium to large lymphoid cells were infrequently seen in hematoxylin and eosin-stained sections in grade 1 biopsies. LYG grades 2 and 3 more consistently had LACs with irregular nuclear contours, vesicular chromatin, and occasional distinct nucleoli, sometimes reminiscent of Hodgkin/Reed-Sternberg cells. Numerous small lymphocytes were always present and admixed with the large atypical lymphoid cells in all grades and showed prominent angiocentricity and angioinvasion. We evaluated 11 patients with concurrent (< 3 mo after initial diagnosis) lung biopsies involving different lobes/segments and found that 9/11 showed the same grade (3 LYG grade 1, 1 LYG grade 2, 5 LYG grade 3), whereas 2 showed different grades (2 LYG grades 2 and 3) ( Table 3 ). We also reviewed the material of 10 patients with subsequent biopsies >3 months after initial diagnosis (range, 4 to 122 mo). Four patients continued to have the same grade (1 LYG grade 1, 1 LYG grade 2, 2 LYG grade 3). Two of the patients with an initial diagnosis of LYG grade 1 progressed to grade 2 and grade 3 despite therapy. Four of the patients with an initial diagnosis of LYG grade 3 had lower-grade lesions on relapse (3 LYG grade 1, 1 LYG grade 2).
We did not regularly see a treatment effect in the biopsies, but there were 2 patients (patients 45, 48; Table 3 ) with a diagnosis of LYG grade 3 who were previously treated at their respective outside institution with chemotherapy (ie, CHOP; cyclophosphamide and prednisone). The posttherapy lung biopsies showed typical features of LYG grade 3, but the necrosis was well circumscribed and surrounded by a distinct thick band of fibrosis ( Fig. 3) .
Immunohistochemistry with CD20 was essential to highlight the LACs and typically showed variable intensity (mainly with LYG grades 2 and 3), similar to EBV infected B cells in other settings. LYG grade 2 and some LYG grade 3 lesions had a T-cell/histiocyte-rich large Bcell-like pattern, or atypical B cells formed small clusters ( Fig. 4 ), whereas grade 3 lesions had larger clusters or small sheets of LAC; however, confluency with obliteration of underlying architecture as with diffuse large B-cell lymphoma (DLBCL) was not seen (Figs. 5, 6). In 15 biopsies in which CD30 was performed, 7/15 (47%) contained frequent positive cells, 5/15 (33%) had rare atypical cells, and 3/15 (20%) were negative. CD15 was performed on 6 biopsies with CD30 positivity, and the lymphoid cells were negative in each case.
The majority of small lymphocytes within the vessel walls were T cells seen with CD3 immunostaining, which was a helpful finding leading to a diagnosis of LYG. CD4-positive T cells were predominant in nearly all cases studied (20/21; 95%) compared with CD8. Light chain restriction was seen in 8/21 biopsies studied (38%) and was predominantly k (5) compared to l (3). Of the 8 light chain restricted biopsies, 4/8 were LYG grade 3, 1/8 LYG grade 2, 1/8 LYG grade 1, and 2/8 could not be further graded.
In situ hybridization for EBV (EBER) stained <5 cells per high-power field (hpf) in LYG grade 1 and was seen in both small and large B cells for all grades. Ten of 22 (46%) grade 1 biopsies were positive for in situ hybridization for EBER. Overall, LYG grade 1 lesions were the most difficult to diagnose because of the paucity of LACs and lack of EBER-positive cells. In LYG grade 2, in situ hybridization for EBER stained <50 cells/hpf, whereas grade 3 lesions had >50 cells/hpf and focally >100/hpf in some areas (Figs. 5D, 6D). Although EBER positivity was mainly seen in the LACs, positive small atypical B cells also were frequently seen. The vast majority of higher-grade LYG biopsies showed expression of EBER. Fifteen of 15 biopsies (100%) of LYG grade 2 and 33/35 (94%) of the LYG grade 3 biopsies were positive for EBER. Of the 2 LYG grade 3 biopsies that were negative for EBER, both were positive for LMP1, with the negative result for EBER due to extensive necrosis and poor preservation of RNA. Overall, considering all of the biopsies for a given patient, 50% of the patients with LYG grade 1 and 100% of the LYG grade 2 and 3 patients had EBV detected in 1 or more biopsies (Table 3 ). It is noteworthy that EBER was performed on 6 bone marrow biopsies for staging, and all were negative. Biopsies from 7 patients were additionally studied for EBNA2 and ZEBRA by immunohistochemistry to assess the latency phenotype of EBV. Five of the 7 cases tested showed positivity for EBNA2, consistent with latency type III. Focal staining for ZEBRA was seen in 2 of the EBNA2-positive cases, whereas all others were negative.
Twenty-five biopsies (5 LYG grade 1; 4 LYG grade 2; 13 LYG grade 3; 3 not further graded) were evaluated (3), GI tract (2), liver (1), nasal cavity (4), conjunctiva (1), and adrenal gland (1) showed similar morphology as LYG in the lung with angioinvasion, polymorphous infiltrate, and EBV-positive LACs (Fig. 7) . Many of the extrapulmonary sites had extensive necrosis with morphologic and immunophenotypic features consistent with LYG grade 3 (7/12, 58%).
Twenty-one skin biopsies were evaluated from 15 patients. Of these, 3 patients (patients 9, 10, 25; Table 3) were described in our previous study. 14 Clinically, 2/21 skin lesions were described as plaques, 2/21 as papules, 6/ 21 as nodules, and 11/21 lesions were not further characterized. All 21 biopsies showed a dense dermal or subcutaneous lymphohistiocytic infiltrate composed of small T lymphocytes and histiocytes, with associated nonnecrotizing granulomatous inflammation in 15/21 (71%) of the biopsies. The infiltrate was frequently confined to the subcutaneous tissue (10/21, 48%), manifesting features of lobular panniculitis (Fig. 8 ). Rimming of fat spaces by T cells was absent, and cytophagocytosis was not observed. Focal necrosis involving subcutis or dermis was seen in 5/21 (24%) of the biopsies. However, the epidermis was spared. Only 4 cases had admixed LACs with CD20 immunostains; these were generally sparse and distributed as single cells. EBER was positive in 3/13 (23%) of the biopsies, but a fourth EBER-negative case was positive for EBNA2 by PCR.
Lung Biopsies in Patients With Underlying Known Immunodeficiencies or Autoimmune Disease With Immunosuppressive Therapies
Three patients had a history of immunosuppressive therapy for underlying disease (rheumatoid arthritis, Crohn disease), and 1 patient had a history of common variable immunodeficiency (Table 3 , patients 52 to 55). The lung biopsies from these patients were histologically indistinguishable from the LYG patients without known history of immunodeficiency. All cases were classified as LYG grade 3.
Molecular Findings
Immunoglobulin gene rearrangement studies were performed by PCR on a total of 44 biopsies. Nineteen (43%) had a clonal rearrangement, 11 (25%) were polyclonal, 6 (14%) had a suspicious or abnormal rearrangement, and 8 (18%) failed to amplify. Of the clonally rearranged cases, 1/12 (8%) was LYG grade 1, 4/ 8 (50%) grade 2, and 11/16 (69%) grade 3 (Table 4) .
T-cell receptor gene rearrangement studies (TRG) were performed on a total of 32 biopsies ( Table 4 ). Two of 32 cases were clonal (6%), 6/32 showed a restricted or abnormal pattern (19%), 22/32 had a polyclonal rearrangement (69%), and 2/32 had no amplification (6%). The 2 biopsies with clonal TRG rearrangement were LYG grade 3 involving the lung.
EBNA2 PCR was performed on 13 biopsies (6 positive; 7 negative). In 2 of the positive cases, EBNA2 PCR detected EBV, whereas EBER by in situ hybridization was negative. Those biopsies showed marked necrosis, compromising RNA integrity for the EBER stain.
DISCUSSION
In practice, the diagnosis of LYG is challenging because the disease is exceedingly rare, and the histologic features can be very subtle. We are in a unique position to describe the pathologic spectrum of disease, as a prospective clinical trial for LYG that has spanned over 20 years is ongoing at the NCI. We have had the opportunity to review 122 biopsies from 55 patients and describe the major clinical and histologic findings of this entity.
LYG is unique clinically and histologically from other B-cell LPDs. Unlike other EBV-associated B-cell normal surrounding lung parenchyma. The histologic features exhibit a spectrum with overlapping features between each subsequent grade.
Histologic examination of the LACs in LYG grades 1 and 2 on hematoxylin and eosin sections was difficult, because the cells were inconspicuous within the background inflammatory cells. Staining with CD20 or CD79a to highlight these LACs was usually necessary to evaluate their density and distribution and to evaluate for angiocentricity. LYG grade 3 had larger aggregates of LACs and occasional small sheets but still could be distinguished from EBV-positive DLBCL, as seen in the elderly. Whereas the latter condition often involves extranodal sites, including the lung, the neoplastic cells exhibit a diffuse growth pattern, with obliteration of the underlying architecture. When necrosis is present it tends to be focal with a patchy distribution and not centered around vessels. 25 Angioinvasion of vessels by T cells is another distinguishing feature of LYG and is helpful in the differential diagnosis with other EBV-related B-cell LPDs. LYG is generally T-cell rich, in comparison with EBV-associated DLBCL.
Contrary to prior case series 3 describing the absence of necrosis in grade 1 lesions, we found that necrosis was more common (29%) than previously thought but usually remained focal (Fig. 2) . Therefore, necrosis can be seen throughout the spectrum of LYG, from grades 1 to 3, and its mere presence does not necessarily indicate a higher grade. However, the presence of "ghost" B cells, as seen by CD20 immunostaining, is usually associated with higher grades, particularly grade 3. The type of necrosis seen was coagulative, lacking inflammatory cells (eg, neutrophils and eosinophils) and apoptotic bodies or "nuclear dust." Extrapulmonary sites were commonly involved and included CNS, liver, skin, and kidney (descending order). Although there were no brain biopsies in this series, CNS involvement was confirmed on the basis of the radiologic characteristics and multifocality of the brain lesions by magnetic resonance imaging in 38% of cases. 26 Evaluation of the CSF by cytomorphology, flow cytometry, and EBNA2 PCR was also performed in many of the cases but was less sensitive (16% positive cases) compared with MRI (38%) ( Table 3 ). The lower sensitivity of CSF PCR may be due to the deeply parenchymal nature of the lesions, sparing the meninges. Besides the skin, the majority of extrapulmonary biopsies were diagnosed as LYG grade 3 on the basis of the number of LACs and EBER-positive B cells (Fig. 7) . This finding was likely skewed because the majority of these biopsies were performed to confirm the clinical suspicion of disease progression or therapy resistance.
The histologic manifestations of LYG in the skin differ from findings observed in the lung and other ex-tranodal sites. The most common finding is subcutaneous panniculitis, with frequent non-necrotizing granulomas. Skin lesions are less often positive for EBER than the lung (23% in the current series), and EBV positivity is usually associated with necrosis in nodular lesions. The findings in our current study are similar to those previously reported by our group in a series of patients studied before 1990. 14 These observations suggest that the cutaneous manifestations are at least in part an epiphenomenon and have a different pathobiology. EBV is known to upregulate the release of cytokines and chemokines, and prior studies have linked the vasculitis of LYG to this phenomenon. 27 Similarly, the cutaneous lesions may be a result of the systemic, rather than local, effects of EBV. Interestingly, the presence of cutaneous lesions did not coincide directly with the presence of active disease in the lung. The pathologic findings in the skin are not specific, although they might suggest the diagnosis of LYG. We have not encountered any case in which LYG was confined to the skin. Other EBV-associated LPDs may present with cutaneous disease and should be considered in the differential diagnosis. 28, 29 Similar to prior studies, 1, 4, 5 the spleen, bone marrow, and lymph nodes were not involved by LYG in our patients. Katzenstein and colleagues also described that enlargement of the spleen and lymph nodes were not common findings. In 42 cases, the lymph nodes biopsied were either normal or had nonspecific findings such as reactive lymphoid hyperplasia. 4 In our study of 35 patients who had bone marrow biopsies, all were negative for involvement by LYG, and only 8 cases had nonspecific findings such as intertrabecular lymphoid or lymphohistiocytic aggregates. Caution should be exercised in diagnosing LYG in a patient with enlarged lymph nodes and splenomegaly.
In a recent review by Katzenstein et al, 30 it was hypothesized that LYG grade 1 may represent improper sampling and that higher-grade lesions are eventually seen with multiple concurrent biopsies. Whether LYG grade 1 exists or is due to sampling is debatable. In our patients who had multiple lung biopsies for monitoring of disease, we found that LYG grade 1 could be seen in other lung fields that were biopsied (3 cases). We also appreciated in the periphery of many LYG grade 2 cases (best seen on wedge biopsies) that small vessels typically had a rich T-cell infiltrate with rare scattered LACs, consistent with an LYG grade 1 lesion (Figs. 4E, F) . In 3/6 patients with LYG grade 3, we found that their posttherapy lung biopsies showed persistent disease with LYG grade 1, suggesting that the low-grade LYG lesions may not be eradicated with chemotherapy. It is important to perform multiple lung biopsies if the patient has multiple lesions to properly grade and choose the most appropriate therapeutic approach. Biopsy of the larger dominant nodules is also advised.
Many of our patients (34/55, 62%) underwent various therapies at their original institution, before being treated at the NCI. The remaining patients had no prior therapy. Patients were then treated with the therapy choice as mentioned above (ie, interferon a or DA-EPOCH-R) on the basis of the grade. High-grade lesions with prominent LACs typically responded to chemotherapy, but some LYG grade 3 cases recurred with a lower-grade disease.
Currently, the 2008 WHO classification uses the number of EBV-positive B cells/hpf as part of the criteria for grading. However, one must be aware of the impact of necrosis in assessing the number of EBER-positive cells. As the areas of necrosis are always negative by in situ hybridization for EBER, this can greatly underestimate the number of EBER-positive cells especially when the necrosis is extensive, as in high-grade lesions. It also should be noted that EBV was not seen only in the large transformed B cells. The EBER-positive cells usually showed a spectrum in cell size, with numerous small B cells being positive for EBER as well. The total number and density of EBER-positive cells were both considered in determining grade in the WHO system. These exceptions, although few, emphasize the importance of factoring in multiple findings to properly grade these lesions.
The greatest difficulty was with the diagnosis of grade 1 lesions. This is not surprising as these lesions usually had a paucity of LACs and may have lacked EBV by in situ hybridization/immunohistochemistry or by PCR. Forty-six percent of the LYG grade 1 biopsies had EBER-positive cells, and 3 of the negative cases were also negative by EBNA2 PCR.
Many factors contributed to the diagnosis. Emphasis was placed on the presence of prominent angioinvasion by small T cells in the absence of other causes for the pulmonary infiltrate. Correlation with clinical features is equally important. In addition, one must rule out technical factors for the absence of EBV. Therefore, is it possible to diagnose LYG in an EBV-negative biopsy? Yes, it is possible only in grade 1 lesions with prominent angiocentricity and in conjunction with a high clinical suspicion. Grade 2 and 3 lesions usually did not pose a problem in grading, because the LACs were more prominent, and EBV was detectable in all cases ( Table 3) .
The EBV latency pattern of LYG was previously reported in a single series of 4 cases. 31 Those authors identified expression of LMP1 and EBNA2 in 2 of 3 EBVpositive cases, suggesting a type III latency pattern. In our study, we confirmed type III latency in 5 of 7 cases tested; ZEBRA was focally positive in 2, suggesting some ongoing lytic activity. The latency III phenotype is associated with defective immune surveillance, such as occurs in posttransplant LPD (PTLD). The EBV-infected B cells in LYG may avoid immune surveillance, not by a physical barrier as in pyothorax-associated lymphomas, but rather because the T cells are dysfunctional in regulating the virally infected cells.
Morice et al 32 reported that the background small T cells were predominantly CD8 compared with CD4. In our study, we found just the reverse. Of the 21 biopsies that had CD4 and CD8 immunostains, we found that nearly all (20/21, 95%) of the cases tested had predominantly CD4-positive T cells (Figs. 1D, E). Tregs are characterized by a specific phenotype (CD4 + CD25 + FOXP3 + ) and have been shown to suppress tumor-specific T-cell immunity in the tumor cell microenvironment, which may contribute to disease progression. 33, 34 Tregs have also been associated with decreased survival in certain solid tumors. 35 We performed FOXP3 immunostaining and found that there were more FOXP3-positive T cells in LYG grade 3 (median 39/10 hpf) versus grade 1 or 2 (median 18/10 hpf), suggesting that an increased number of Tregs in grade 3 may contribute to disease progression. Interestingly, Karube et al 36 also showed an increased frequency of EBV-positive cells in FOXP3-positive adult T-cell leukemia/lymphoma cases compared with negative cases, suggesting suppression by Tregs on the T-cell immunosurveillance for EBV. Although our sample size is small, the data are suggestive of a possible role in progression, and a larger group of cases should be investigated.
The differential diagnosis for LYG includes inflammatory disorders such as Wegener granulomatosis, EBV-associated B-cell LPDs such as PTLD, senile or age-related B-cell LPD, Hodgkin lymphoma, and T-cell or NK-cell lymphomas (eg, extranodal NK/T-cell lymphoma, nasal type; peripheral T-cell lymphoma, not otherwise specified). Extranodal NK/T-cell lymphomas, nasal type, can be difficult to differentiate from LYG, because both lesions are EBV-associated, angiocentric, and can involve sites such as the lung, but other sites such as GI tract and nasal cavity are unusual for LYG. In addition, the pattern of necrosis differs with more numerous apoptotic debris not generally seen in LYG. Additional studies for immunoglobulin gene rearrangement or double-labeling to determine the immunophenotype of the EBER-positive cells can be helpful in such cases.
There were 2 cases that had a clonal T-cell gene rearrangement (TRG). Both of these cases were LYG grade 3 involving the lung. Although T cells were abundant, the large neoplastic cells were clearly of B-cell lineage. Restricted or even clonal TRG may be associated with EBV infection. 25, 37 This phenomenon is believed to be the result of the expansion of a few dominant T-cell clones reacting to EBV viral epitopes. 37 Paradoxically, restricted or clonal T-cell responses are more likely to be seen in patients with less effective control of EBV and chronic or persistent EBV infection. 38 Occasionally, the differential diagnosis for LYG may include classical Hodgkin lymphoma (CHL). The EBER-positive LACs in LYG are often CD30-positive, but CD15 is negative. However, variable expression of CD20 may be present, as often seen in CHL. In CHL positive for EBV, the EBER-positive cells do not show variation in cell size, as is typical in LYG. In addition, Hodgkin lymphoma should be favored if there is evidence of lymph node involvement, which is virtually never seen in LYG.
Patients with an underlying acquired or inherited immunodeficiency syndrome may be diagnosed with LYG (eg, Wiskott Aldrich syndrome, X-linked lymphoproliferative syndrome, HIV/AIDS, solid organ transplant) under the current WHO classification. In this study, we focused on the biopsies from patients without an underlying acquired or inherited immunodeficiency. However, a few cases from patients who had an underlying immunodeficiency (ie, common variable immunodeficiency) or receiving prolonged immunosuppressive regimens related to underlying autoimmune disease (eg, rheumatoid arthritis) showed features indistinguishable from LYG.
Other EBV-associated B-cell LPDs such as PTLD may present more of a challenge and at times may show overlap with LYG. There were some findings that were helpful in this distinction, such as lack of T-cell angioinvasion, relatively T-cell "poor" lesions in relation to the B cells (Table 5) , and prominent plasmacytic differentiation, all features characteristic of polymorphic PTLD. In addition, in contrast to EBV-associated B-cell LPDs, the nodules in LYG were typically well circumscribed, with smaller nodules rich in small T cells in an angiocentric distribution often seen at the periphery (Figs. 4E, F) . Nearly all patients studied by EBV serology showed evidence of past exposure but had a low median viral load (18 copies/10 6 genome equivalents). This is in contrast to patients with PTLD who typically have elevated median viral loads (mean of 544,750 EBV copies/mL, range 74,000 to 3,200,000). 39 However, if the clinical picture is consistent with LYG (multiple lung lesions, sparing of the lymph nodes, spleen, bone marrow, and low peripheral blood viral load) and the lesions have morphologic and immunophenotypic features consistent with LYG, we feel that a diagnosis of LYG can be made in the post transplant setting.
In summary, from our experience, the following findings were helpful in confirming a diagnosis of LYG (Table 6 ). Clinically, the patient must have pulmonary involvement, usually multifocal lesions with a predilection for the lower lobes. Extrapulmonary sites are common and may be seen with disease progression. Histologically, the infiltrate is polymorphous, composed of predominantly small T cells and LACs (number dependent on grade) with an angiocentric distribution. Immunohistochemistry for CD20 is imperative to highlight the LACs in LYG grades 1 and 2, and CD3 is very helpful in highlighting the angioinvasion by the T cells. CD4-positive T cells usually predominate over CD8, and the surrounding lung parenchyma should be largely normal. For grading, the number of LACs and EBERpositive cells should be used, and, although necrosis (coagulative-type) is more extensive in higher grades, it can also be seen in grade 1 lesions. If EBER is negative by in situ hybridization and if clinical suspicion for LYG is high, one might consider PCR for EBV/EBNA2 sequences for confirmation; otherwise we recommend additional lung biopsies if multiple lesions are seen clinically. 
